Matching articles for "fam-trastuzumab"

In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • April 3, 2023;  (Issue 1673)
Fam-trastuzumab deruxtecan-nxki (Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of...
Fam-trastuzumab deruxtecan-nxki (Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of response,1 has been granted regular approval for treatment of adults with unresectable or metastatic HER2-positive breast cancer who received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed recurrence during or within 6 months of completing treatment.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e60-1 | Show Full IntroductionHide Full Introduction